FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 534 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends to Extend the Indications for Tislelizumab May 8, 2025 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July June 25, 2025 Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 ASCO 2021 news: follow-up treatments pave the way June 9, 2021 Load more HOT NEWS Handmade Artisan Gifts For Under $30 How My Cancer Diagnosis Has Fueled My Work in Improving Access... Shelter Puppies Got A Private Tour Of The Georgia Aquarium Why people and culture matter in research
